Amgen Seeks FDA Nod For Bone Drug

12/19/08

Amgen, the world’s largest biotech company, said today it has applied for FDA clearance to sell denosumab for women with osteoporosis and to treat and prevent bone loss for certain patients with prostate or breast cancer. The drug showed in clinical trials it can lower the risk of spinal fractures, a finding that analysts say could propel it to more than $2 billion in annual sales. Amgen (NASDAQ: AMGN) has research centers in Seattle and Cambridge, MA.

By posting a comment, you agree to our terms and conditions.

  • MARY LESTER

    I JUST WENT TO THE DRUGSTORE TO GET MY MEDICATION AND FOUND OUT THAT IT WOULD COST ME 191.OO DOLLARS FOR SENISPAR. I CAN IN NO WAY AFFORD THIS SINCE BOTH ME AND MY HUSBAND ARE DISABLED. I AM ON DALYSIS 3 DAYS A WEEK FOR 4 HOURS EACH DAY. I WOULD NOT BE BEGGING YOUR HUMAN RESOURCES BUT MY BACKS UP AGAINST THE WALL AND I DONT KNOW WHAT TO DO . IF ANYONE COULD DONATE MY MEDICATION I WOULD BE SO THANKFUL. I CAN PROVIDE AMY DOCUMENTATION FROM MY DOCTOR OR DIALYSIS CENTER. THANK YOU